Nirupama Mulherkar

News

Combo produces responses in R/R Ph+ ALL

Author:: Nirupama Mulherkar

Publish date: January 8, 2018

ATLANTA—A 2-drug combination has produced a high response rate in a small trial of patients with relapsed/refractory (R/R), Philadelphia chromosome-po...

News

Combo shows promise for elderly/unfit ALL patients

Author:: Nirupama Mulherkar

Publish date: January 4, 2018

ATLANTA—Results of a phase 2 trial suggest treatment with ponatinib and steroids is feasible for patients with acute lymphoblastic leukemia (ALL) who ...

News

Cell-free DNA mutational analysis in AITL

Author:: Nirupama Mulherkar

Publish date: March 9, 2017

SAN FRANCISCO—An exploratory study suggests cell-free DNA from peripheral blood may be a viable alternative to tumor DNA for mutational profiling in a...

News

Pathogenesis of breast-implant-associated ALCL

Author:: Nirupama Mulherkar

Publish date: March 7, 2017

SAN FRANCISCO—A small study suggests an abnormal immune response characterized by the production of interleukin-13 (IL-13) underlies the pathogenes...

News

Study sheds light on genetic landscape of HSTL

Author:: Nirupama Mulherkar

Publish date: March 6, 2017

SAN FRANCISCO—Researchers say they have identified new driver genes and oncogenic pathways in hepatosplenic T-cell lymphoma (HSTL). The team found ...

News

Consortium to undertake longitudinal study of acquired TTP

Author:: Nirupama Mulherkar

Publish date: January 10, 2017

SAN DIEGO—The US Thrombotic Microangiopathies (USTMA) Consortium is planning a longitudinal study to identify biomarkers of relapse and neurocog...